Novartis agreed to pay $125 million to acquire a blood-brain barrier delivery platform from Sironax, giving Novartis global rights to a technology designed to transport multiple drug modalities across the BBB. The deal is positioned to advance three candidates Sironax says have “best-in-class” potential. The acquisition comes as Novartis faces ongoing neuroscience pipeline setbacks, and reflects a continued emphasis on central nervous system delivery solutions—an area where efficacy often hinges on pharmacokinetic access to brain tissue. Sironax’s platform is centered on BBB crossing, intended to expand the set of modalities that can reach targets in the CNS. Novartis’s purchase tightens control of the underlying IP for delivery and supports internal development plans after several pipeline disappointments in the neuroscience portfolio.